FDA Memberikan Penunjukan Penyakit Langka Pediatric untuk SAT-3247 untuk Mengobati Distrofi Otot Duchenne

Artikel Terkait

FDA Menyetujui Vimseltinib untuk Pengobatan Pasien Dewasa dengan TGCT Simptomatik

24 Februari 2025

FDA Memberikan Penunjukan Fast Track untuk 67Cu-SAR-bisPSMA dalam Pengobatan Kanker Prostat

24 Februari 2025

Chenodiol, Pengobatan Pertama untuk Cerebrotendinous Xanthomatosis, Mendapat Persetujuan FDA

24 Februari 2025

Referensi

1. Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy. Satellos. News release. August 8, 2024. Accessed August 9, 2024. https://www.businesswire.com/news/home/20240808320005/en/Satellos-Receives-Rare-Pediatric-Disease-Designation-from-the-U.S.-FDA-for-SAT-3247-for-the-Treatment-of-Duchenne-Muscular-Dystrophy

2. Duchenne Muscular Dystrophy. National Library of Medicine. News release. July 10, 2023. Accessed August 9, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482346/#:~:text=Duchenne%20muscular%20dystrophy%20(DMD)%20is%20one%20of%20the%20most%20severe,muscle%20fiber%20degeneration%20and%20weakness.

3. Lambert P. LB: SAT-3247: An Oral Small Molecule Inhibitor Targeting AAK1, a Critical Effector Of Skeletal Muscle Regeneration. MDA Clinical & Scientific Conferece. March 2024. Accessed August 9, 2024. https://www.mdaconference.org/abstract-library/sat-3247-an-oral-small-molecule-inhibitor-targeting-aak1-a-critical-effector-of-skeletal-muscle-regeneration/

4. Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247. Satellos. News release. July 11, 2024. Accessed August 9, 2024. https://ir.satellos.com/news/news-details/2024/Satellos-Announces-Submission-of-Regulatory-Filing-to-Commence-a-Phase-1-Clinical-Trial-with-SAT-3247/default.aspx